Clinicopathological Features of Pakistani Patients with Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD)

Muhammad Zain Arshad; Muhammad Omair Riaz; Dawood Ahmad; Muhammad Hussain; Ayesha Tanveer; Maryam Bibi

doi:10.51253/pafmj.v74i6.9945

Authors

Muhammad Zain Arshad Department of Immunology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Muhammad Omair Riaz Department of Immunology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Dawood Ahmad Department of Immunology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Muhammad Hussain Department of Immunology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Ayesha Tanveer Department of Radiology, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Maryam Bibi Department of Radiology, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i6.9945

Keywords:

Anti Myelin Oligodendrocyte Glycoprotein Antibody, Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease, Optic Neuritis, Transverse Myelitis.

Abstract

Objective: To characterize clinicopathological features of patients with Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease in local population for early diagnosis and treatment.

Study Design: Cross-sectional study.

Place and Duration of Study: Department of Immunology, Armed Forces Institute of Pathology, Rawalpindi Pakistan, from Jun 2021 to Jan 2023.

Methodology: Our study involved consecutive random sampling of 400 individuals presenting at Armed Forces Institute of Pathology for serum Anti Myelin Oligodendrocyte Glycoprotein antibody testing by indirect immunofluorescence. Commercial Anti Myelin Oligodendrocyte Glycoprotein Antibody Indirect Immunofluorescence Test Slides along with controls were used and immunofluorescence was observed using fluorescent microscope BA-310. Detailed data was collected on a predesigned proforma, and qualitative and quantitative variables were analysed using statistical software.

Results: Eleven (2.75%) patients were positive for Anti Myelin Oligodendrocyte Glycoprotein antibodies with a male to female ratio of 1.6:1 (p =0.882). Mean age of diagnosis was 30.3±12 years. At time of diagnosis, all patients had 2 or more core clinical characteristics, of which, most prevalent was transverse myelitis, optic neuritis and headache/fever present in 4(80%) patients. The average diagnostic delay in our study was 20 months.

Conclusions: By having a high index of suspicion for presenting core clinical characteristics of Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease, clinicians may be able to diagnose and treat this rare ailment in a timely manner to decrease diagnostic delay and prevent associated morbidity and mortality.

Downloads

Download data is not yet available.

References

Boziki M, Sintila SA, Ioannidis P, Grigoriadis N. Biomarkers in rare demyelinating disease of the central nervous system. Int J Mol Sci 2020; 21(21): 8409.

https://doi.org/10.3390/ijms21218409

Ambrosius W, Michalak S, Kozubski W, Kalinowska A. Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management. Int J Mol Sci 2020; 22(1).

https://doi.org/10.3390/ijms22010114

Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 2016; 15(4): 307-324. https://doi.org/10.1016/j.autrev.2016.01.007

de Mol CL, Wong YYM, van Pelt ED, Wokke BHA, Siepman TAM, Neuteboom RF, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler J 2019; 26(7): 806-814.

https://doi.org/10.1177/1352458519864922

Ong ZM, Arip M, Ching YM, Kumar L, Terumalay S, Sim SH, et al. The prevalence, demographics, clinical features, neuroimaging, and inter-ethnic differences of MOGAD in Malaysia with global perspectives. Mult Scler Relat Disord 2022; 67: 104168.

https://doi.org/10.1016/j.msard.2022.104168

Messias K, Marques VD, Messias A. Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: an update. Arq Bras Oftalmol 2023; 86.

https://doi.org/10.1590/0004-2749-2023-0004

Mariotto S, Gajofatto A, Batzu L, Delogu R, Sechi G, Leoni S, et al. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology 2019; 93(20): e1867-e1872.

https://doi.org/10.1212/WNL.0000000000008450

Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2018; 25: 66-72.

https://doi.org/10.1016/j.msard.2018.07.017

Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 2023; 22: 122–131.

https://doi.org/10.1016/S1474-4422(22)00460-7

Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol 2022; 13.

https://doi.org/10.3389/fneur.2022.886588

Sechi E, Buciuc M, Pittock SJ, Chen JJ, Fryer JP, Jenkins SM, et al. Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA Neurol 2021; 78(6): 741-746.

https://doi.org/10.1001/jamaneurol.2021.0966

Orlandi R, Mariotto S, Gajofatto A. Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, Italy. Mult Scler Relat Disord 2022; 63: 103884. https://doi.org/10.1016/j.msard.2022.103884

Sutton P, Lutz MW, Hartsell FL, Kimbrough D, Tagg NT, Skeen M, et al. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: presentation and outcomes of adults at a single center. J Neuroimmunol 2022; 373: 577987.

https://doi.org/10.1016/j.jneuroim.2022.577987

Asseyer S, Hamblin J, Messina S, Mariano R, Siebert N, Everett R, et al. Prodromal headache in MOG-antibody positive optic neuritis. Mult Scler Relat Disord 2020; 40: 101965.

https://doi.org/10.1016/j.msard.2020.101965

Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2019; 15(2): 89-102. https://doi.org/10.1038/s41582-018-0112-x

Rempe T, Tarhan B, Rodriguez E, Viswanathan VT, Gyang TV, Carlson A, et al. Anti-MOG associated disorder: clinical and radiological characteristics compared to AQP4-IgG+ NMOSD: a single-center experience. Mult Scler Relat Disord 2021; 48: 102718.

https://doi.org/10.1016/j.msard.2020.102718

Li Y, Liu X, Wang J, Pan C, Tang Z. Clinical features and imaging findings of myelin oligodendrocyte glycoprotein-IgG-associated disorder (MOGAD). Front Aging Neurosci 2022; 14.

https://doi.org/10.3389/fnagi.2022.841052

Bartels F, Lu A, Oertel FC, Finke C, Paul F, Chien C. Clinical and neuroimaging findings in MOGAD–MRI and OCT. Clin Exp Immunol 2021; 206(3): 266-281.

https://doi.org/10.1111/cei.13666

Dauby S, Dive D, Lutteri L, Andris C, Hansen I, Maquet P, et al. Comparative study of AQP4-NMOSD, MOGAD, and seronegative NMOSD: a single-center Belgian cohort. Acta Neurol Belg 2022; 122(1): 135-144.

https://doi.org/10.1007/s13760-021-01719-x